Novel targeted therapies in the treatment of soft-tissue sarcomas

2010 ◽  
Vol 10 (8) ◽  
pp. 1303-1311 ◽  
Author(s):  
Joseph Chao ◽  
Warren A Chow ◽  
George Somlo
Keyword(s):  
Soft Tissue ◽  
Targeted Therapies ◽  
Soft Tissue Sarcomas

scholarly journals Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to know

2013 ◽  
Vol 13 (2) ◽  
pp. 197-211 ◽  
Author(s):  
Sree Harsha Tirumani ◽  
Jyothi P. Jagannathan ◽  
Kevin O Regan ◽  
Kyung Won Kim ◽  
Atul B. Shinagare ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Targeted Therapies ◽  
Soft Tissue Sarcomas ◽  
Molecular Targeted Therapies

Targeted therapies for soft-tissue sarcomas

2007 ◽  
Vol 7 (5) ◽  
pp. 725-733 ◽  
Author(s):  
William D Tap ◽  
Noah Federman ◽  
Fritz C Eilber
Keyword(s):  
Soft Tissue ◽  
Targeted Therapies ◽  
Soft Tissue Sarcomas

scholarly journals Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1737 ◽  
Author(s):  
Jennifer Choe ◽  
Richard Riedel
Keyword(s):  
Soft Tissue ◽  
Rare Disease ◽  
Targeted Therapies ◽  
Systemic Treatment ◽  
Soft Tissue Sarcomas ◽  
The Body ◽  
Connective Tissues ◽  
Histologic Subtype ◽  
Treatment Practices ◽  
Recent Emergence

Sarcomas are rare tumors derived from mesenchymal connective tissues in the body. Because there are well over 50 histologic sarcoma subtypes, including malignant and non-malignant pathologies, clinical courses and therapeutic management are widely divergent. In general, therapeutic options across all soft tissue sarcomas are limited in number and are often generalized across multiple sarcoma histologies. The recent emergence of molecularly targeted therapies and immune-based agents presents a future of refined systemic treatment practices that are rationally tailored to the tumor by histologic subtype and biologic mechanisms.

scholarly journals Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas

Sarcoma ◽  
2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Jun Wang ◽  
Arielle Elkrief ◽  
Wei Guo ◽  
Neerav Shukla ◽  
Mrinal Gounder ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Cancer Treatment ◽  
Targeted Therapies ◽  
Soft Tissue Sarcomas ◽  
Present Review ◽  
Epigenetic Drugs ◽  
Clinical Utilization ◽  
Chromatin Configuration ◽  
Epigenetic Regulators

Targeted therapies have revolutionized cancer treatment. It is well established that alterations of chromatin configuration and modifications affect tumorigenesis of some, possibly most, bone and soft-tissue sarcomas. As epigenetic regulators play a major role in the development of bone and soft-tissue sarcomas, epigenetic drugs provide a novel potential avenue for rational targeted therapies for these aggressive cancers. The present review summarizes the application of epigenetic drugs for clinical utilization in bone and soft-tissue sarcomas and provides an overview of clinical trials currently evaluating epigenetic therapies in this space.

scholarly journals The Evolving Role of Radiotherapy for Pediatric Cancers With Advancements in Molecular Tumor Characterization and Targeted Therapies

2021 ◽  
Vol 11 ◽  
Author(s):  
Colette J. Shen ◽  
Stephanie A. Terezakis
Keyword(s):  
Soft Tissue ◽  
Molecular Diagnostics ◽  
Targeted Therapies ◽  
Soft Tissue Sarcomas ◽  
Critical Element ◽  
Precision Oncology ◽  
Tumor Characterization ◽  
Pediatric Cancers ◽  
Systemic Therapies

Ongoing rapid advances in molecular diagnostics, precision imaging, and development of targeted therapies have resulted in a constantly evolving landscape for treatment of pediatric cancers. Radiotherapy remains a critical element of the therapeutic toolbox, and its role in the era of precision medicine continues to adapt and undergo re-evaluation. Here, we review emerging strategies for combining radiotherapy with novel targeted systemic therapies (for example, for pediatric gliomas or soft tissue sarcomas), modifying use or intensity of radiotherapy when appropriate via molecular diagnostics that allow better characterization and individualization of each patient’s treatments (for example, de-intensification of radiotherapy in WNT subgroup medulloblastoma), as well as exploring more effective targeted systemic therapies that may allow omission or delay of radiotherapy. Many of these strategies are still under investigation but highlight the importance of continued pre-clinical and clinical studies evaluating the role of radiotherapy in this era of precision oncology.

Targeted therapies in adult soft tissue sarcomas

2007 ◽  
Vol 95 (3) ◽  
pp. 183-184 ◽  
Author(s):  
Jia-Lin Yang ◽  
Philip J. Crowe
Keyword(s):  
Soft Tissue ◽  
Targeted Therapies ◽  
Soft Tissue Sarcomas
Sign in / Sign up

Export Citation Format

Share Document